IP Library › Granted Patent US 8,951,999
Granted Patent B2
US 8,951,999 · App. 12/908,172 · Granted Feb 10, 2015

Compounds

Inventors: Henning Priepke (Warthausen, DE); Henri Doods (Warthausen, DE); Raimund Kuelzer (Mittlelbiberach, DE); Roland Pfau (Biberach, DE); Dirk Stenkamp (Biberach, DE); Robert Roenn (Uppsala, SE); Benjamin Pelcman (Uppsala, SE)
Assignee: Orexo AB
C07D213/82C07C237/42C07C237/44C07C255/23C07C255/60C07C311/14C07D205/04C07D207/10C07D207/22C07D207/34C07D209/08C07D211/14C07D211/16C07D211/18C07D211/38C07D213/40C07D213/75C07D213/81C07D215/42C07D237/30C07D277/46C07D277/56C07D277/60C07D277/82C07D295/15C07D295/155C07D307/20C07D307/24C07D309/12C07D309/14C07D333/38C07D335/02C07D417/04C07C2101/02C07C2101/04C07C2101/08C07C2101/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,951,999
App. No.
12/908,172
Granted
Feb 10, 2015
Kind
B2
Abstract

This invention relates to compounds of formula I, their use as inhibitors of the microsomal prostaglandin E 2 synthase-1 (mPGES-1), pharmaceutical compositions containing them, and their use as medicaments for the treatment and/or prevention of inflammatory diseases and associated conditions such as inflammatory/nociceptive pain. A, M, R 1 , R 2 , R 7 , R a , R b , Q 3 , Q 4 , Q 6 , Z 2 , Z 4 , Z 5 , Z 6 and W have meanings given in the description.

Claims (180)

1. A compound selected from the following compounds:

#

Structure

1

2

3

4

5

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

179

180

181

or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising at least one compound according to claim 1 , or a pharmaceutically acceptable salt thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent and/or carrier.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 20, 2014
From: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
To: OREXO AB
Reel/Frame 033986/0609 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 22, 2011
From: PRIEPKE, HENNING; DOODS, HENRI; KUELZER, RAIMUND; PFAU, ROLAND; STENKAMP, DIRK; ROENN, ROBERT; PELCMAN, BENJAMIN
To: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
Reel/Frame 025994/0483 →
Priority Claims (1)
EP 09173872 · Oct 23, 2009 · regional
Continuity (1)
Related Publication 20110263556A1 · Oct 27, 2011